SINGAPORE, April 2, 2026 /PRNewswire/ — LightInTheBox Holding Co., Ltd. (NYSE: LITB) (“LightInTheBox” or the “Company”), a global consumer lifestyle company, today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission (“SEC”). An electronic copy of the annual report on Form 20-F can be accessed on LightInTheBox’s investor relations website at https://ir.ador.com and on the SEC’s website at https://www.sec.gov. Shareholders may receive a hard copy of LightInTheBox’s audited financial statements for the fiscal year ended December 31, 2025 free of charge upon request. Requests should be submitted to [email protected].
About LightInTheBox Holding Co., Ltd.
Founded in 2007, LightInTheBox is a global direct-to-consumer (DTC) e-commerce company dedicated to delivering a joyful lifestyle to consumers worldwide. Leveraging AI-driven market insights and agile supply chain systems, it aims to capture consumer preferences and sentiment to offer differentiated products, driving consumer engagement through deep emotional resonance. LightInTheBox also adopts a brand matrix strategy by launching its own apparel brands such as Ador to further strengthen its position as a consumer lifestyle company. Additionally, LightInTheBox offers a comprehensive suite of services to e-commerce companies, including advertising, supply chain management, payment processing, order fulfillment, and shipping and delivery solutions.
For more information, please visit https://ir.ador.com.
Investor Relations Contact
Investor Relations
LightInTheBox Holding Co., Ltd.
Email: [email protected]
Serena Huang
Octans Capital Group
Email: [email protected]
ข่าวที่เกี่ยวข้อง
- Anchanto Expands Partnership with Stanley Black & Decker, Powering South Korea’s First Omnichannel Shopping Experience for Tools
- แมนพาวเวอร์กรุ๊ป ติดหนึ่งในสุดยอดนายจ้างแห่งเอเชียแปซิฟิก จากการจัดอันดับของ TIME Asia-Pacific’s Best Employers 2027
- ASADOR ETXEBARRI IS NAMED NO.1 IN THE LIST OF THE 50 BEST RESTAURANTS 2026
- Abbott and Novo expand partnership to launch Plosbrio® broadening access to semaglutide for advanced diabetes care across Asia Pacific
